BMO Capital analyst Jeffrey Silber lowered the firm’s price target on AMN Healthcare (AMN) to $22 from $27 and keeps an Outperform rating on the shares. The company again delivered a margin-driven beat to consensus, though while hospital commentary had been improving, the recent government policies and macro volatility softened volumes, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare Services: Hold Rating Maintained Amid Weaker Demand and Uncertain Recovery
- AMN Healthcare Reports Q2 2025 Financial Results
- AMN Healthcare reports Q2 adjusted EPS 30c, consensus 19c
- AMN Healthcare sees Q3 revenue $610M-$625M, consensus $640.12M
- AMN Healthcare (AMN) Q2 Earnings Cheat Sheet